Aspire Biopharma Holdings (ASBP) Profit After Tax (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Profit After Tax data on file, last reported at -$3.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 79.78% year-over-year to -$3.2 million in Q1 2026; TTM through Mar 2026 was -$11.8 million, a 30.89% increase from a year earlier, with the FY2025 full-year figure at -$24.5 million, down 1768.95% from the prior year.
• Profit After Tax for Q1 2026 stood at -$3.2 million, up from -$4.7 million in the prior quarter.
• Over the last five years, Profit After Tax for ASBP reached as high as $2.9 million in Q1 2023 and fell as low as -$15.9 million in Q1 2025.
• Historically, Profit After Tax has averaged -$1.2 million across 5 years, with a median of -$150913.0 in 2023.
• Across the five-year window, Profit After Tax jumped 295484.64% in 2022 and plunged 6801.9% in 2025, its largest moves.
• Year by year, Profit After Tax stood at $2.2 million in 2022, then sank by 106.77% to -$150913.0 in 2023, then sank by 407.39% to -$765710.0 in 2024, then plunged by 514.82% to -$4.7 million in 2025, then soared by 31.54% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$3.2 million in Q1 2026, -$4.7 million in Q4 2025, and -$1.9 million in Q3 2025.